Shanghai - Delayed Quote CNY

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (688266.SS)

99.49
+3.99
+(4.18%)
At close: May 9 at 3:00:04 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
592,351.93
532,954.37
386,438.78
302,305.06
190,360.57
Cost of Revenue
49,310.06
36,991.45
29,212.10
26,161.02
6,268.58
Gross Profit
543,041.86
495,962.93
357,226.69
276,144.04
184,091.98
Operating Expense
715,872.94
683,282.25
682,947.97
779,967.41
686,722.90
Operating Income
-172,831.08
-187,319.32
-325,721.29
-503,823.37
-502,630.92
Net Non Operating Interest Income Expense
28,932.31
29,189.92
14,903.31
13,803.91
33,777.25
Pretax Income
-139,741
-155,047.81
-299,084.51
-487,954.73
-465,147.22
Tax Provision
-4,760.10
-4,749.48
-3,949.56
-2,449.46
-3,156.39
Net Income Common Stockholders
-126,593.63
-137,830.78
-278,582.74
-457,327.72
-450,999.17
Basic EPS
-0.48
-0.52
-1.09
-1.91
-1.88
Diluted EPS
-0.48
-0.52
-1.09
-1.91
-1.88
Basic Average Shares
263,459.23
265,059.18
255,580.50
239,438.60
239,893.18
Diluted Average Shares
263,459.23
265,059.18
255,580.50
239,438.60
239,893.18
Total Operating Income as Reported
-139,435.93
-155,043.18
-297,782.40
-485,557.49
-459,044.29
Rent Expense Supplemental
--
1,404.98
1,319.69
1,712.58
3,386.53
Total Expenses
765,183.01
720,273.70
712,160.07
806,128.43
692,991.49
Net Income from Continuing & Discontinued Operation
-126,593.63
-137,830.78
-278,582.74
-457,327.72
-450,999.17
Normalized Income
-128,149.45
-137,986.02
-285,595.48
-457,999.78
-448,959.74
Interest Income
57,827.45
58,287.81
39,354.99
28,745.44
39,977.62
Interest Expense
29,086.48
28,892.92
22,552.73
12,031.55
4,417.20
Net Interest Income
28,932.31
29,189.92
14,903.31
13,803.91
33,777.25
EBIT
-110,654.52
-126,154.88
-276,531.78
-475,923.18
-460,730.01
EBITDA
-110,654.52
-70,555.48
-221,701.98
-409,554.32
-409,959.01
Reconciled Cost of Revenue
49,310.06
36,991.45
29,212.10
26,161.02
6,268.58
Reconciled Depreciation
--
55,599.41
54,829.80
66,368.86
50,771
Net Income from Continuing Operation Net Minority Interest
-126,593.63
-137,830.78
-278,582.74
-457,327.72
-450,999.17
Total Unusual Items Excluding Goodwill
1,610.69
160.15
7,106.59
675.45
-2,053.37
Total Unusual Items
1,610.69
160.15
7,106.59
675.45
-2,053.37
Normalized EBITDA
-112,265.21
-70,715.63
-228,808.57
-410,229.77
-407,905.65
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
54.87
4.91
93.85
3.39
-13.93
12/31/2021 - 1/23/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6XC.F Soleno Therapeutics, Inc.
64.85
+1.25%
 
688177.SS Bio-Thera Solutions, Ltd.
21.92
-1.17%
 
25I.SG ImmuPharma PLC
0.0295
0.00%
 
XUPB.F Genfit S.A.
3.7800
-0.53%
 
328.SG MeiraGTx Holdings PLC
4.8400
+0.83%
 
22Z.SG Zealand Pharma A/S
56.18
-6.30%
 
688428.SS InnoCare Pharma Limited
20.56
+0.54%
 
BSFAF BSF Enterprise Plc
0.0584
0.00%
 
CSJA.F CSL Limited
66.50
0.00%
 
ABRT.CN Albert Labs International Corp.
0.0050
0.00%